Sage Therapeutics, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Sage Therapeutics, Inc. – Product Pipeline Review – 2016’, provides an overview of the Sage Therapeutics, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sage Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Sage Therapeutics, Inc.

The report provides overview of Sage Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Sage Therapeutics, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Sage Therapeutics, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Sage Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Sage Therapeutics, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Sage Therapeutics, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Sage Therapeutics, Inc. Snapshot 5

Sage Therapeutics, Inc. Overview 5

Key Information 5

Key Facts 5

Sage Therapeutics, Inc. - Research and Development Overview 6

Key Therapeutic Areas 6

Sage Therapeutics, Inc. - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Sage Therapeutics, Inc. - Pipeline Products Glance 11

Sage Therapeutics, Inc. - Late Stage Pipeline Products 11

Phase III Products/Combination Treatment Modalities 11

Sage Therapeutics, Inc. - Clinical Stage Pipeline Products 12

Phase II Products/Combination Treatment Modalities 12

Phase I Products/Combination Treatment Modalities 13

Sage Therapeutics, Inc. - Early Stage Pipeline Products 14

IND/CTA Filed Products/Combination Treatment Modalities 14

Preclinical Products/Combination Treatment Modalities 15

Discovery Products/Combination Treatment Modalities 16

Sage Therapeutics, Inc. - Drug Profiles 17

sepranolone 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

SAGE-217 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

SAGE-689 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

SAGE-105 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

SAGE-324 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

SAGE-718 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

SGE-872 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Small Molecules to Agonize NMDA Receptor for Cognitive Disorders 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Small Molecules to Agonize NMDA receptor for CNS Disorders 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Small Molecules to Modulate GABAA Receptor for CNS Disorders 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Sage Therapeutics, Inc. - Pipeline Analysis 29

Sage Therapeutics, Inc. - Pipeline Products by Target 29

Sage Therapeutics, Inc. - Pipeline Products by Route of Administration 30

Sage Therapeutics, Inc. - Pipeline Products by Molecule Type 31

Sage Therapeutics, Inc. - Pipeline Products by Mechanism of Action 32

Sage Therapeutics, Inc. - Recent Pipeline Updates 33

Sage Therapeutics, Inc. - Dormant Projects 39

Sage Therapeutics, Inc. - Locations And Subsidiaries 40

Head Office 40

Appendix 41

Methodology 41

Coverage 41

Secondary Research 41

Primary Research 41

Expert Panel Validation 41

Contact Us 41

Disclaimer 42

List of Tables

List of Tables

Sage Therapeutics, Inc., Key Information 5

Sage Therapeutics, Inc., Key Facts 5

Sage Therapeutics, Inc. – Pipeline by Indication, 2016 8

Sage Therapeutics, Inc. – Pipeline by Stage of Development, 2016 9

Sage Therapeutics, Inc. – Monotherapy Products in Pipeline, 2016 10

Sage Therapeutics, Inc. – Phase III, 2016 11

Sage Therapeutics, Inc. – Phase II, 2016 12

Sage Therapeutics, Inc. – Phase I, 2016 13

Sage Therapeutics, Inc. – IND/CTA Filed, 2016 14

Sage Therapeutics, Inc. – Preclinical, 2016 15

Sage Therapeutics, Inc. – Discovery, 2016 16

Sage Therapeutics, Inc. – Pipeline by Target, 2016 29

Sage Therapeutics, Inc. – Pipeline by Route of Administration, 2016 30

Sage Therapeutics, Inc. – Pipeline by Molecule Type, 2016 31

Sage Therapeutics, Inc. – Pipeline Products by Mechanism of Action, 2016 32

Sage Therapeutics, Inc. – Recent Pipeline Updates, 2016 33

Sage Therapeutics, Inc. – Dormant Developmental Projects,2016 39

List of Figures

List of Figures

Sage Therapeutics, Inc. – Pipeline by Top 10 Indication, 2016 7

Sage Therapeutics, Inc. – Pipeline by Stage of Development, 2016 9

Sage Therapeutics, Inc. – Monotherapy Products in Pipeline, 2016 10

Sage Therapeutics, Inc. – Pipeline by Target, 2016 29

Sage Therapeutics, Inc. – Pipeline by Route of Administration, 2016 30

Sage Therapeutics, Inc. – Pipeline by Molecule Type, 2016 31

Sage Therapeutics, Inc. – Pipeline Products by Mechanism of Action, 2016 32

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports